HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of cyclic AMP formation in N1E-115 neuroblastoma cells is mediated by a non-cardiac M2 muscarinic receptor subtype.

Abstract
The cardioselective muscarinic antagonist, AF-DX 116 [11[2-[(diethyl-amino)-methyl]-O-1-piperidinyl]-5,11-dihydro-6H-pyrido- [2,3-b][1,4]-benzodiazepine-6-one), was weak at blocking the M2 muscarinic receptor-mediated inhibition of cyclic adenosine monophosphate (cAMP) formation in mouse neuroblastoma cells (clone N1E-115). In contrast, the glandular-selective antagonists, hexahydro-sila-difenidol (HHSiD) and 4-diphenylacetoxy-N-methyl-piperidine methiodide (4-DAMP), were quite potent at inhibiting this response, being 14- and 318-fold more potent than AF-DX 116 in this regard, respectively. According to the rank order of potency of these two classes of antagonists, these data provide the first pharmacological evidence that inhibition of cAMP formation in a neuronal tissue is mediated by a non-cardiac M2 muscarinic receptor subtype.
AuthorsW Surichamorn, C L Amrhein, C Forray, E E el-Fakahany
JournalBrain research (Brain Res) Vol. 493 Issue 2 Pg. 320-5 (Jul 31 1989) ISSN: 0006-8993 [Print] Netherlands
PMID2548669 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Muscarinic Antagonists
  • Piperidines
  • Receptors, Muscarinic
  • Scopolamine Derivatives
  • 4-diphenylacetoxy-1,1-dimethylpiperidinium
  • Cyclic AMP
  • hexahydrosiladifenidol
  • N-Methylscopolamine
Topics
  • Animals
  • Binding, Competitive
  • Cyclic AMP (metabolism)
  • Mice
  • Muscarinic Antagonists
  • N-Methylscopolamine
  • Neuroblastoma
  • Piperidines (pharmacology)
  • Receptors, Muscarinic (classification, metabolism)
  • Scopolamine Derivatives (metabolism)
  • Tumor Cells, Cultured (drug effects, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: